Ibrutinib

ब्रांड नाम

Nepal brand names not included: no licence-safe source.

What it is used for

is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. Adult patients with Waldenström’s macroglobulinemia (WM).

How it works

Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.

Common side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage Infections Cardiac Arrhythmias, Cardiac Failure, and Sudden Death Hypertension Cytopenias Second Primary Malignancies Hepatotoxicity, including DILI Tumor Lysis Syndrome The most common (≥30%) adverse reactions in patients with B-cell...

Do not use if (contraindications)

None None

Pregnancy & breastfeeding

Pregnancy (label summary): Risk Summary IMBRUVICA can cause fetal harm based on findings from animal studies. There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to a fetus.

सामान्य प्रश्न

What is Ibrutinib used for?
is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. Adult patients with Waldenström’s macroglobulinemia (WM).

How does Ibrutinib work?
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.

What are the side effects of Ibrutinib?
The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage Infections Cardiac Arrhythmias, Cardiac Failure, and Sudden Death Hypertension Cytopenias Second Primary Malignancies Hepatotoxicity, including DILI Tumor Lysis Syndrome The most common (≥30%) adverse reactions...

Who should not take Ibrutinib?
None None

Can I take Ibrutinib in pregnancy or while breastfeeding?
Pregnancy (label summary): Risk Summary IMBRUVICA can cause fetal harm based on findings from animal studies. There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to a fetus.

What is the dose of Ibrutinib?
Not provided here. Ask a doctor or pharmacist.

Ibrutinib क्या है?
Ibrutinib is used for: is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). It belongs to the class: Kinase Inhibitor. Common side effects include: The following clinically significant adverse reactions are described elsewhere …

Ibrutinib कैसे काम करती है?
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.